Diversified Trust Co Sells 502 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Diversified Trust Co cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.2% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,343 shares of the company’s stock after selling 502 shares during the quarter. Diversified Trust Co’s holdings in IDEXX Laboratories were worth $725,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in IDXX. Valley National Advisers Inc. increased its position in IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares in the last quarter. Riverview Trust Co bought a new position in IDEXX Laboratories in the 1st quarter worth approximately $26,000. Geo Capital Gestora de Recursos Ltd acquired a new position in IDEXX Laboratories during the 3rd quarter worth $28,000. DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth $33,000. Finally, Venturi Wealth Management LLC boosted its position in IDEXX Laboratories by 226.3% in the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $477.23 on Wednesday. The company has a market capitalization of $39.41 billion, a price-to-earnings ratio of 46.21, a P/E/G ratio of 3.97 and a beta of 1.32. The firm’s 50 day simple moving average is $501.52 and its 200 day simple moving average is $526.04. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now directly owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IDXX shares. Morgan Stanley dropped their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Finally, Barclays reduced their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.